Expertise in
12
conditions

Elie J. Haddad

Montreal, QC, CA 
Expertise in
12
conditions
Montreal, QC, CA 

Overview

Elie Haddad practices practicing medicine in Montreal, Canada.

Mr. Haddad is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Severe Combined Immunodeficiency (SCID), Chronic Granulomatous Disease, Atresia of Small Intestine, Primary Immunodeficiency (PID), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 176 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Montreal, QC, Canada
Other Locations
Montreal, Canada
Quebec, QC H3T1C5, Canada
Vancouver, BC, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
Enrollment Status: Completed
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Emapalumab
Study Phase: Phase 3
An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
Enrollment Status: Completed
Publish Date: December 09, 2022
Intervention Type: Biological
Study Phase: Phase 3
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Enrollment Status: Unknown
Publish Date: September 02, 2021
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
Enrollment Status: Unknown
Publish Date: November 12, 2020
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
Enrollment Status: Enrolling_by_invitation
Publish Date: November 10, 2020
Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)
Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)
Enrollment Status: Completed
Publish Date: August 10, 2020
View 5 Less Clinical Trials

176 Total Publications

Functional stratification of MEFV variants by flow cytometric assessment of pyrin inflammasome activation.
Functional stratification of MEFV variants by flow cytometric assessment of pyrin inflammasome activation.
Journal: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
Published: March 09, 2026

Frequently Asked Questions about Elie J. Haddad

Is Elie J. Haddad a top-rated expert for Severe Combined Immunodeficiency (SCID)?

MediFind is an objective health platform that identifies experts based on real-world data. Elie J. Haddad is classified as an Elite expert for Severe Combined Immunodeficiency (SCID), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Elie J. Haddad participate in research or clinical trials?

Yes. Elie J. Haddad has published 176 articles and abstracts on conditions like Severe Combined Immunodeficiency (SCID). You can view a list of Elie J. Haddad's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Haddad's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 42 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile